Harrow, Inc. (HROW): Operating Cash Flow
$43.86M
Year ended 2025-12-31
$6.25M
Trailing 12 months to 2026-06-30
+195.2%
3-year compound annual growth
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $43.86M | n/m | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | -$22.20M | n/m | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | $3.84M | +125.2% | 2026-03-02, From 2023-01-01 |
| 2022-12-31 | $1.71M | -66.5% | 2024-03-19, From 2022-01-01 |
| 2021-12-31 | $5.08M | n/m | 2023-03-23, From 2021-01-01 |
| 2020-12-31 | -$1.10M | n/m | 2022-03-10, From 2020-01-01 |
| 2019-12-31 | $950.0K | +38.3% | 2021-03-08, From 2019-01-01 |
| 2018-12-31 | $687.0K | n/m | 2020-03-13, From 2018-01-01 |
| 2017-12-31 | -$8.80M | n/m | 2019-03-12, From 2017-01-01 |
| 2016-12-31 | -$11.21M | n/m | 2018-03-08, From 2016-01-01 |
| 2015-12-31 | -$11.14M | n/m | 2017-03-21, From 2015-01-01 |
| 2014-12-31 | -$7.06M | n/m | 2016-03-23, From 2014-01-01 |
| 2013-12-31 | -$4.44M | n/m | 2015-03-12, From 2013-01-01 |
| 2012-12-31 | -$1.90M | n/m | 2014-03-28, From 2012-01-01 |
| 2011-12-31 | -$291.2K | n/m | 2013-03-18, From 2011-01-01 |
| 2010-12-31 | -$2.30M | n/a | 2012-02-23, From 2010-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Harrow, Inc. (HROW) | 2025-12-31 | $43.86M | n/m |
| Vireo Growth Inc. (VREOF) | 2025-12-31 | $3.71M | n/m |
| Ligand Pharmaceuticals Inc (LGND) | 2025-12-31 | $49.36M | -49.1% |
| Arvinas, Inc. (ARVN) | 2025-12-31 | -$273.80M | n/m |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $13.90M | n/m |
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $28.63M | n/m |
| Ironwood Pharmaceuticals Inc (IRWD) | 2025-12-31 | $127.04M | +22.7% |
| Evolus, Inc. (EOLS) | 2025-12-31 | -$42.27M | n/m |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | -$482.00M | n/m |
Compare HROW, VREOF, LGND, ARVN side by side · Screen every company in Pharmaceutical Preparations ↗